Data Vantage: ImmunoScape, Swingvy, PaySense and Aktivolabs receive funding

Data Vantage: ImmunoScape, Swingvy, PaySense and Aktivolabs receive funding

This web version of the DATA VANTAGE twice-weekly premium newsletter is available only to our premium subscribers. Unlock access by picking up any of our premium subscription plans.

Pre-clinical biotech company ImmunoScape received $6 million from Amgen Ventures, the corporate venture capital arm of US-based biopharma firm Amgen, last week. The investment is part of a $14 million financing announced in September.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter